Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase I Bridging Study to Evaluate the Pharmacokinetics, Safety and Tolerability of SR750 (Formulation F1) in Chinese Healthy Subjects

NCT06932536 is registered in ClinicalTrials.gov with Shanghai SIMR Biotechnology Co., Ltd. as lead sponsor.

NCT NCT06932536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06932536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase I Bridging Study to Evaluate the Pharmacokinetics, Safety and Tolerability of SR750 (Formulation F1) in Chinese Healthy Subjects
Lead sponsor
Shanghai SIMR Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
April 28, 2025
Completion date
July 7, 2025
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy